EU Biotech Act and the MDR–AI Act relationship divide the medtech sector
Under the draft EU Biotech Act, AI-based devices would keep their "high-risk" classification while much of the underlying safeguards would be removed. MedTech Europe is urging a single regulatory pathway, and the relationship between the MDR and the AI Act remains contested.
Who is affected and how
- medtech company
- Given the parallel compliance burdens under the MDR and the AI Act, companies should align their compliance plans with the current proposals.
- health policy
- The dispute over removing patient-safety safeguards is a question to be settled in the legislative process.
- doctor
- How devices are classified and checked determines how far clinicians can rely on them in clinical use.
Sources
- The EU Biotech Act Puts Medical AI Safeguards at a Crossroads | Pharmaticapharmatica.io · Oct 12, 2026
- EU MDR and the AI Act (Annex I medical devices) | AI Assurance Directoryaiassurancedirectory.com · Oct 15, 2026
- EU healthcare and industry groups urge single AI regulatory pathway by integrating AI Act high-risk requirements into MDR/IVDR for AI-enabled medical devices and diagnostics - Legal News - LexisNexis UKlexisnexis.com · Oct 15, 2026
- Towards a single regulatory pathway for AI-enabled medical technologies - MedTech Europemedtecheurope.org · Oct 15, 2026
- COCIR - European Coordination Committee of the[...] (via Public) / Towards a Single Regulatory Pathway for AI-Enabled Medical Technologiesebs.publicnow.com · Oct 15, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.